Synonyms: Example 124 [US20190023662] [2] | OPB171775
Compound class:
Synthetic organic
Comment: OPB-171775 is a molecular glue [3]. Structurally it is a PDE3A inhibitor derivative. In gastrointestinal stromal tumour cells it promotes formation of a ternary complex with phosphodiesterase 3A (PDE3A) and schlafen family member 12 (SLFN12). PDE3A/SLFN12 complex formation activates the pro-apoptotic ribonuclease activity of SLFN12, which results in a cytotoxic antitumour effect [1]. This molecular mechanism is proposed as an alternative to tyrosine kinase inhibitor (TKI)-based cancer therapies, particularly for TKI-resistant tumours.
|
|
References |
1. de Waal L, Lewis TA, Rees MG, Tsherniak A, Wu X, Choi PS, Gechijian L, Hartigan C, Faloon PW, Hickey MJ et al.. (2016)
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol, 12 (2): 102-8. [PMID:26656089] |
2. Katoh T, Iida M, Terauchi Y, Yamaguchi K, Hirose T, Yokoyama F, Nishimori H, Obuchi Y, Nabeshima H, Takaki E. (2019)
5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative. Patent number: US20190023662A1. Assignee: Otsuka Pharmaceutical Co Ltd. Priority date: 02/03/2017. Publication date: 24/01/2019. |
3. Takaki EO, Kiyono K, Obuchi Y, Yamauchi T, Watanabe T, Matsumoto H, Karimine M, Kuniyoshi Y, Nishikori S, Yokoyama F et al.. (2024)
A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. Clin Cancer Res, 30 (16): 3603-3621. [PMID:38864850] |